At the news
? NEUTRALIMPACT 5/10 8-K/A filed Nov 9, 2026 at 16:39 ET
This 8-K/A amends the original 8-K to provide historical financial statements of Theravance Biopharma and unaudited pro forma combined financials for Zymeworks following its acquisition of Theravance, which closed on September 23, 2026. Theravance shareholders received $17.00 per share in cash plus contingent value rights tied to ampreloxetine. The cash consideration was partly financed via $350 million in non-recourse notes from OMERS Life Sciences, secured by YUPELRI profit-share cash flows. Pro forma combined net income for the nine months ended September 30, 2026 was $11.8 million ($0.16 basic EPS), compared to a pro forma net loss of $43.7 million for FY 2025.
- Zymeworks completed acquisition of Theravance on September 23, 2026, with Theravance becoming a wholly owned subsidiary.
- Theravance shareholders received $17.00 per share in cash plus one contingent value right (CVR) per share.
- CVRs entitle holders to 80% of net proceeds from ampreloxetine monetization, $50M upon first commercial sale in specified countries, and 10% of net sales.
- Total consideration for outstanding shares and equity awards was $915.6 million, net of $355.2 million cash acquired, resulting in net consideration of $560.4 million.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access